Cargando…

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL

Chondroitin-sulfate proteoglycan 4 (CSPG4) is a transmembrane glycoprotein overexpressed on malignant cells in several cancer types with only limited expression on normal cells. CSPG4 is implicated in several signaling pathways believed to drive cancer progression, particularly proliferation, motili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jordaan, Sandra, Chetty, Shivan, Mungra, Neelakshi, Koopmans, Iris, van Bommel, Peter E., Helfrich, Wijnand, Barth, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618295/ https://www.ncbi.nlm.nih.gov/pubmed/28657611 http://dx.doi.org/10.3390/biomedicines5030037

Ejemplares similares

Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells
por: Mungra, Neelakshi, et al.
Publicado: (2019)

Human MAP Tau Based Targeted Cytolytic Fusion Proteins
por: Akinrinmade, Olusiji A., et al.
Publicado: (2017)

Human Granzyme B Based Targeted Cytolytic Fusion Proteins
por: Hlongwane, Precious, et al.
Publicado: (2018)

Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation
por: Bochicchio, Anna, et al.
Publicado: (2017)

CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate
por: Mungra, Neelakshi, et al.
Publicado: (2023)

Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells
por: Jordaan, Sandra, et al.
Publicado: (2018)

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
por: Hendriks, Djoke, et al.
Publicado: (2016)

A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members
por: He, Yuan, et al.
Publicado: (2017)

Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins
por: Tur, Mehmet Kemal, et al.
Publicado: (2017)

Recent advances in immunotherapies against infectious diseases
por: Ramamurthy, Dharanidharan, et al.
Publicado: (2020)

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
por: Bremer, Edwin, et al.
Publicado: (2008)

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
por: de Bruyn, Marco, et al.
Publicado: (2010)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
por: Naran, Krupa, et al.
Publicado: (2018)

The regulatory mechanisms of NG2/CSPG4 expression
por: Ampofo, Emmanuel, et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

Direct transfer of antigen-specific cytolytic activity to noncytolytic cells upon fusion with liposomes derived from cytolytic T cell clones
Publicado: (1984)

Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
por: Nicolosi, Pier Andrea, et al.
Publicado: (2015)

Localization and Developmental Expression Patterns of CSPG in the RCS Rat Retina
por: Chen, Li-Feng, et al.
Publicado: (2011)

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

Cspg4(high) microglia contribute to microgliosis during neurodegeneration
por: Liu, Ya-jing, et al.
Publicado: (2023)

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
por: Hendriks, Mark A. J. M., et al.
Publicado: (2020)

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
por: Schiffer, Davide, et al.
Publicado: (2018)

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
por: Zhang, Hongyu, et al.
Publicado: (2022)

Sustained Delivery of Activated Rho GTPases and BDNF Promotes Axon Growth in CSPG-Rich Regions Following Spinal Cord Injury
por: Jain, Anjana, et al.
Publicado: (2011)

Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
por: Riccardo, Federica, et al.
Publicado: (2019)

NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis
por: Reed, David A., et al.
Publicado: (2022)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
por: Teppert, Karin, et al.
Publicado: (2023)

Scoping review of cytolytic vaginosis literature
por: Kraut, Roni, et al.
Publicado: (2023)

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells
por: Britsch, Isabel, et al.
Publicado: (2023)

On the Trail of Linked Selection
por: Josephs, Emily B., et al.
Publicado: (2016)

Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Two PTP receptors mediate CSPG inhibition by convergent and divergent signaling pathways in neurons
por: Ohtake, Yosuke, et al.
Publicado: (2016)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells
por: Wang, Chris Kedong, et al.
Publicado: (2022)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Helper or cytolytic functions can be selectively induced in bifunctional T cell clones
Publicado: (1990)

CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases
por: Akinrinmade, Olusiji A., et al.
Publicado: (2017)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

The isolation and testing of cytolytic factor.
por: Mackay, W. D., et al.
Publicado: (1966)

Cannot write session to /tmp/vufind_sessions/sess_ukfvma9eakhpmsgdcuhf83r6ll